Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor ConferenceGlobeNewsWire • 09/03/24
Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer'sSeeking Alpha • 07/30/24
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer's DiseaseGlobeNewsWire • 07/29/24
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC®) 2024GlobeNewsWire • 07/28/24
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business HighlightsGlobeNewsWire • 05/14/24
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceGlobeNewsWire • 05/13/24
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare ConferenceGlobeNewsWire • 05/08/24
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's DiseaseGlobeNewsWire • 05/08/24
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual MeetingGlobeNewsWire • 04/16/24
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's DiseaseGlobeNewsWire • 04/04/24
Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 03/28/24
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business HighlightsGlobeNewsWire • 03/26/24
Is Acumen Pharmaceuticals (ABOS) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 03/21/24
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024GlobeNewsWire • 03/19/24
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual MeetingGlobeNewsWire • 03/08/24
Has Acumen Pharmaceuticals (ABOS) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 02/29/24
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual MeetingGlobeNewsWire • 02/21/24
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development OfficerGlobeNewsWire • 02/01/24